Clinical features and disease management in adult patients with atopic dermatitis receiving care at reference hospitals in brazil: The adapt study

Página do item simplificado
dc.contributor.authorArruda L.K.
dc.contributor.authorYang A.C.
dc.contributor.authorAoki V.
dc.contributor.authorCriado R.F.J.
dc.contributor.authorPires M.C.
dc.contributor.authorLupi O.
dc.contributor.authorFabricio L.H.Z.
dc.contributor.authorRichman D.
dc.contributor.authorSilvi S.
dc.date.accessioned2024-03-12T19:23:19Z
dc.date.available2024-03-12T19:23:19Z
dc.date.issued2021
dc.description.abstract© 2021 Esmon Publicidad.Background: Atopic dermatitis is a chronic inflammatory skin disease with a prevalence of 0.02% to 8.1% in adults. Adult patients with moderate-to-severe atopic dermatitis are affected by frequent relapses and a significant disease burden. Objective: To determine the clinical, immunological, and therapeutic profile of Brazilian adults with atopic dermatitis. Methods: A multicenter, observational, retrospective, descriptive registry-based study was conducted at reference hospitals between December 2016 and October 2017. The data collected were demographics, personal and family history of atopic diseases, clinical manifestations, laboratory tests, disease severity and management. Results: Of the 187 patients included in the analysis, 56.1% were female and 71.7% were White, with a mean age of 24.7 years. Mean follow-up was 9 years. Asthma or other allergic diseases were reported by 80.2% of patients. The main comorbidity was hypertension (10.2%), and common disease manifestations included pruritus and erythema. Lesions generally affected flexural and nonflexural areas, with typical morphology. Around 83% of patients had moderate-to-severe disease, and 8.6% reported at least 1 hospitalization. Most patients received topical and/or systemic pharmacological therapies, including omalizumab (5.9%); 4.3% received phototherapy. Moreover, 66.8% of patients received adjuvant therapy, and 79.1% changed or discontinued treatment for atopic dermatitis due to remission (46.5%), poor effectiveness (33.7%), or lack of adherence (12.9%). Most patients presented characteristics of type 2 inflammation, with immunoglobulin E levels above 100 IU/mL (94.4%) and peripheral blood eosinophils above 5% (55.9%). Conclusion: Brazilian adult patients with severe atopic dermatitis need treatment to efficiently control the disease and improve quality of life.
dc.description.firstpage236
dc.description.issuenumber3
dc.description.lastpage245
dc.description.volume31
dc.identifier.doi10.18176/jiaci.0478
dc.identifier.issn1698-0808
dc.identifier.urihttps://dspace.mackenzie.br/handle/10899/34814
dc.relation.ispartofJournal of Investigational Allergology and Clinical Immunology
dc.rightsAcesso Aberto
dc.subject.otherlanguageAdult
dc.subject.otherlanguageAtopic dermatitis
dc.subject.otherlanguageDisease management
dc.subject.otherlanguageEpidemiologic study characteristics
dc.subject.otherlanguageTertiary care centers
dc.titleClinical features and disease management in adult patients with atopic dermatitis receiving care at reference hospitals in brazil: The adapt study
dc.typeArtigo
local.scopus.citations7
local.scopus.eid2-s2.0-85103681224
local.scopus.subjectAdult
local.scopus.subjectBrazil
local.scopus.subjectComorbidity
local.scopus.subjectDemography
local.scopus.subjectDermatitis, Atopic
local.scopus.subjectDisease Progression
local.scopus.subjectEosinophils
local.scopus.subjectErythema
local.scopus.subjectFemale
local.scopus.subjectFollow-Up Studies
local.scopus.subjectHospitalization
local.scopus.subjectHumans
local.scopus.subjectHypertension
local.scopus.subjectImmunoglobulin E
local.scopus.subjectMale
local.scopus.subjectOmalizumab
local.scopus.subjectPruritus
local.scopus.subjectTertiary Care Centers
local.scopus.updated2024-05-01
local.scopus.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85103681224&origin=inward
Arquivos
Coleções
Artigos de periódico